Company ProfilePremium

1300SMILES Limited

Company Profile Analysis

Ticker: ONT.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
1300SMILES Limited - Company showcase

Year Founded & Workforce

1991

338 Employees

1300SMILES Limited logo

1300SMILES Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

1300SMILES Limited Overview

1300SMILES Limited is a regional-Queensland-anchored dental services organisation (DSO). It built a 33-practice network concentrated in Queensland's ten largest population centres plus a small New South Wales presence. Its model is service-centric. The company owns the surgeries, equipment and support staff and provides billing, marketing, accreditation and procurement. Self-employed dentists practise inside its facilities under Dental Service Agreements and pay the company a share of their production. For two decades under founder Dr Daryl Holmes, the company was distinctive among ASX dental roll-ups for its conservatism: modest leverage, owner-like capital allocation, uninterrupted fully franked dividends from listing, and a disciplined, opportunistic approach to acquisitions. That record culminated in a FY2021 result of A$65.8m over-the-counter revenue and A$9.6m NPAT. It then sold to BGH Capital and OTPP-backed Abano Healthcare at 13.5x underlying pre-AASB 16 EBITDA. Today it is a regional brand inside one of Australasia's largest dental platforms.


Company's own description (Annual Report FY2021, paraphrased)

1300SMILES described itself as the owner and operator of full-service dental facilities in New South Wales and in Queensland's ten major population centres. It stated an intention to expand into other Australian regions, both by opening its own sites and by acquiring established practices. Corporate and administrative functions sit in Townsville.

The operating model works as follows:

  • The company provides dental surgeries, practice management and related services to self-employed dentists who run their own practices.

  • Those dentists pay fees under a Dental Service Agreement.

  • In some cases the company employs dentists directly.

Services provided to dentists include:

  • Marketing

  • Administration

  • Billing and collections

  • Facility certification and licensing

  • All support staff, equipment and facilities

  • Group-level purchasing of consumables

The dentist base ranges from new graduates to experienced practitioners. Some have special interests in endodontics, oral surgery, implants and periodontics and cross-refer within the network.

The stated growth drivers (Annual Report FY2021) were:

  1. Attracting more dentists to existing facilities and expanding those at full capacity.

  2. Lifting the turnover of existing dentists through benchmarking, training and mentoring.

  3. Greenfield practices in existing and new regions.

  4. Acquiring substantial practices on favourable terms.

  5. Managing dental facilities owned by others.

Independent characterisation

Business model. 1300SMILES is best understood as a dental infrastructure-and-services landlord with operating leverage, not a clinical provider in the accounting sense. The economic engine is the gap between over-the-counter (OTC) patient billings and what the company retains after dentists take their share.

The company reported both measures. In FY2021:

  • OTC revenue (total patient fees billed through its practices) was A$65.8m.

  • A$20.8m was retained by self-employed dentists.

  • Statutory revenue was therefore A$44.9m.

The implied company retention ratio was about 68% of OTC billings (derived). This is consistent with a model where the company carries the full fixed cost base (staff, premises, equipment, consumables), and the dentist's share is effectively a variable cost.

Revenue model mix (FY2021, Note 5 and Note 6).

  • Services, in the form of DSA service fees: 96.8%

  • Financial and other income: 3.2%

  • Product, subscription and licensing revenue: not material as separate lines

A membership/treatment-plan revenue stream (the "$1-a-day Dental Care Plan") was recognised over time. It was disclosed only within receivables (A$0.2m at 30 June 2021), not as a separate revenue line.

Value chain position. 1300SMILES sits between upstream suppliers and downstream payers:

  • Upstream: dental consumables and equipment suppliers, dental labs, landlords, and the dentist labour market.

  • Downstream: patients and payers, including out-of-pocket patients, private health insurers (the website lists preferred-provider relationships with Medibank, nib, Bupa, HCF, CBHS, Westfund, Defence Health and TUH), and the Commonwealth Child Dental Benefits Schedule (CDBS).

Customer types. The company has two customer classes:

  • Dentists, who are the contractual customers paying service fees.

  • Patients, who are the economic end-users: families, children (CDBS), adults seeking general, restorative and cosmetic care, and regional populations under-served by public dental services.

End-markets. The end-market is Australian private general dental services, with a regional Queensland focus (Townsville, Cairns, Mackay, Rockhampton, Gladstone, Bundaberg, Toowoomba, the Sunshine Coast and Greater Brisbane) and a small Sydney footprint (Cammeray).

Strategy

Stated strategy at delisting

Annual Report FY2021, paraphrased themes:

Core objective: keep growing profits and shareholder returns while giving staff and dentists a rewarding environment.

Organic growth: recruit dentists into under-utilised chairs, expand full-capacity sites, and lift dentist productivity through benchmarking and mentoring.

Greenfields: new practices in existing and new regions.

Acquisitions: opportunistic, on favourable terms only. Management repeatedly stressed it would not buy or keep practices just to inflate site counts (MD letter, February 2020).

Third-party management: managing dental facilities owned by others.

The FY2021 outlook listed three likely developments: ongoing opportunistic acquisitions, continued organic growth of existing practices, and ongoing investigation of greenfield sites.

Initiatives in the final 24 months as a listed company (Sep 2019 – Dec 2021)

InitiativeDateDetailSource
Pursuit of Maven Dental (116 practices)H2 CY2019A transformational bid that would have roughly quadrupled scale. Lost to BGH/OTPP's whole-company bid for AbanoBusiness News Australia
Smiles Inclusive opportunismDecember 2019Bought two healthy practices from the distressed peer rather than the whole companyBusiness News Australia
CBA facility and accordionAugust 2019A$50m headroom for an acquisition programNote 24
COVID-19 cash conservationMarch–September 2020Practice closures, NED fee waivers, JobKeeper (A$4.0m over FY2020–FY2021)Annual Report FY2021; Kalkine
Central/Western Queensland bolt-onsDecember 2020 – August 2021Bundaberg Central Point, Chinchilla, fourth Bundaberg practiceAnnual Report FY2021
Sale to AbanoAugust–December 2021Strategic exit; brand integrated into the Abano platformASX announcements

Post-acquisition strategy (under Abano)

At announcement, Abano positioned 1300SMILES as a complementary addition to its Australian network of 106 practices (largely Maven Dental). Its CEO cited BGH Capital's and Ontario Teachers' experience in healthcare as support for clinician outcomes and the next phase of growth.

The 1300SMILES website now presents it as an Abano Group brand alongside Maven and Lumino. Abano's careers platform recruits for all brands. Under prior listed ownership, Abano articulated a goal of 10% share of the roughly NZ$11bn trans-Tasman dental market (NBR). Current Abano targets are not publicly disclosed.

Not publicly disclosed: medium-term financial targets, ESG commitments and cost programs specific to 1300SMILES.

Products & Services

All offerings sit within the single reportable segment. Clinical services are delivered by independent (self-employed) or employed dentists operating from 1300SMILES facilities. The company's direct "product" is the practice platform. "Launch year" denotes the first public reference found, not necessarily the true launch date.

Platform services sold to dentists (B2B)

OfferingDescriptionTarget customerPricing modelSource
Dental Service Agreement (DSA)Turnkey surgery access: chairs, equipment, support staff, reception, sterilisationSelf-employed general dentists and specialistsService fee retained from dentist production (company retained ~68% of OTC in FY2021, derived)Annual Report FY2021
Practice management and administrationBilling, collections, health-fund claiming, schedulingDSA dentistsBundled in DSAAnnual Report FY2021
MarketingGroup brand, 1300 number, digital booking, patient offersDSA dentistsBundledAnnual Report FY2021
Accreditation and licensingQIP practice accreditation; radiation licences (Radiation Safety Act 1999 (Qld), Radiation Control Act 1990 (NSW)); trade waste approvalsDSA dentistsBundledSIA "Material Licence" definition
ProcurementGroup buying of consumables and lab servicesDSA dentistsBundledAnnual Report FY2021
Benchmarking, training, mentoringPerformance coaching to lift dentist turnoverDSA dentistsBundledAnnual Report FY2021
Practice acquisition / exit pathwayBuys owner-dentists' practices; the vendor typically stays through an earn-outRetiring or practice-owning dentistsCash plus contingent earn-outAnnual Report FY2021 (Chinchilla, Bundaberg)
Facility management for third partiesManaging dental facilities owned by others (stated growth driver)Third-party owners—Annual Report FY2021
Share-loan incentive programCompany-funded loans for consultants, contractors and executives to buy shares (3.5% interest, escrowed, full recourse)Key dentists and executivesA$1.65m principal outstanding at June 2021Note 14

Patient-facing clinical services (B2C, delivered through the network)

CategoryNamed servicesNotes
General dentistryCheck-ups, cleans, x-rays, fillings, dentures (incl. immediate dentures), emergency dentistryCurrent new-patient offer: check-up, clean and bitewing x-rays for A$249 at participating practices (valid to 15 January 2027)
PreventativeFissure seals, custom mouthguards, bruxism/TMJ management, sleep apnoea oral appliancesMouthguard promotion tied to Queensland school-sport requirements
RestorativeFillings, root canal therapy, crowns, bridges, implants, dentures—
CosmeticTeeth whitening (in-chair and take-home), veneers, composite bonding, smile makeovers—
OrthodonticsBraces, Invisalign®, ClearCorrect aligners, QuickStraightTeeth, Fast Braces, early (interceptive) treatment, adult orthodonticsThird-party aligner brands; not proprietary
Children's dentistryCDBS servicesWebsite states all clinics support CDBS (benefit cap stated as A$1,052)
Specialist-interest careEndodontics, oral surgery, implants, periodontics via internal cross-referralAnnual Report FY2021

Sources: company website (October 2026) and blogs.

Patient financing and membership products

ProductDescriptionLaunch / first referencePricingSource
$1-a-day Dental Care PlanMembership plan bundling preventive careReferenced FY2014–FY2015About A$1 per dayPress releases, February 2014 and August 2015
1300SMILES DMA VouchersIn-house financing for higher-value treatment~FY2015From A$99 per weekPress release, 18 August 2015
"Drill now, pay later" financingDeferred-payment optionsReferenced in AFR coverage—AFR company page
Third-party BNPLHUMM, ZIP Health, AfterpayCurrentProvider termsWebsite, 2026
Membership discounts and offersCurrent membership/discount schemeCurrent—Website, 2026
Health-fund preferred providerMedibank, nib, Bupa, HCF, CBHS, Westfund, Defence Health, TUH (not all funds at all sites)CurrentFund schedulesWebsite, 2026

Financial Narrative

Basis.

  • FY2020 and FY2021 come from the audited Annual Report FY2021.

  • FY2017 to FY2019 revenue series come from the multi-year reconciliation in the FY2021 MD letter.

  • FY2019 EBITDA comes from the FY2021 EBITDA bridge.

  • FY2019 NPAT and EPS are derived from FY2020 NPAT of A$7.145m, reported as down about 8.1% year on year (Stockhead; Business News Australia).

  • FY2022 onwards are not publicly disclosed (private company).

  • AASB 16 (leases) applies from FY2020. FY2019 and earlier are pre-AASB 16, so EBITDA is not like-for-like.

Income statement

Sources: Annual Report FY2021 (income statement, EBITDA bridge, Notes 7 to 10); InvestSMART dividend history (FY2017 to FY2021 interim and final amounts); FNN (FY2020 dividend).

EBITDA bridge (Annual Report FY2021, AUD '000).

Note on a source conflict. Press coverage in August 2020 cited JobKeeper of about A$1.27m in FY2020 EBITDA. The audited FY2021 Annual Report shows FY2020 JobKeeper receipts of A$1.805m. The audited figure is preferred. Separately, Market Index displays FY2020 "NPAT before abnormals" of A$6.72m and "EPS with abnormals" of 28.37c, which differ from the audited A$7.145m and 30.2c. The aggregator figures are treated as unreliable.

Margins and growth

All margins are derived from the figures in 6.1.

Revenue CAGR FY2017–FY2021 (derived):

  • OTC: 6.6%

  • Statutory: 5.5%

Commentary. The five-year arc has three phases.

FY2017–FY2019: steady organic and acquisitive growth: OTC rose from A$51.0m to A$58.9m, helped by FY2019 acquisitions (Springfield Lakes, Maroochydore, Strathpine Central).

FY2020: a COVID-19 shock that the accounts partly mask: OTC fell 3.1% after practices were largely closed between 23 March and 11 May 2020. Underlying pre-AASB 16 EBITDA fell 17% to A$8.7m. Reported EBITDA rose 22%, but only because of AASB 16 (which moves rent below EBITDA), JobKeeper and one-off items. Management disclosed that revenue had been running more than 7% ahead year on year over the first three quarters, and that June 2020 was the best month in company history.

FY2021: an inflection: OTC grew 15% to a record A$65.8m. Underlying pre-AASB 16 EBITDA rose 39% to A$12.2m, and NPAT rose 35%. Same-store sales for the 26 practices operating throughout FY2019 and FY2020 were 8% (A$4m) above FY2019. During FY2019–FY2021 the company disposed of six practices and acquired six, showing active portfolio pruning.

The operating leverage is visible: dentists' share of OTC rose (A$16.4m to A$20.8m), but fixed costs (premises, support staff) grew more slowly, so incremental OTC dropped through at high rates. Second-half FY2021 moderated because of the post-lockdown catch-up in 1H and intermittent SEQ/NSW lockdowns.

Balance sheet

Source: Annual Report FY2021 (balance sheet, Notes 11, 14, 17 to 19, 24, statement of changes in equity, cash flow opening balance).

Commentary.

  • The balance sheet is goodwill-heavy. Goodwill was 71% of equity at June 2021. Net tangible assets were only 44.0c per share (including right-of-use items), which is typical of a practice roll-up.

  • Bank debt was conservative. Net leverage was 0.60x against a 2.75x covenant, and fixed-charge cover was 6.09x against a 1.80x floor.

  • The CBA facility (A$25m plus A$25m accordion, 1.89% at June 2021) was due to terminate on 2 August 2022 and was refinanced or replaced at the Abano level after the takeover.

  • A notable and unusual item is A$6.0m of redeemable preference shares in an unlisted public company, yielding 2.75% to 12% over 3 to 36 months (Note 14). The SIA separately barred any new investment in "Investors Central Limited" as a prescribed event. That suggests the counterparty, but the annual report does not name it, so this is an inference only.

  • Treasury-style investments of this kind in a dental operator were a governance and liquidity consideration flagged by the acquirer.

Cash flow

Source: Annual Report FY2021, cash flow statement.

Commentary.

  • Cash conversion was strong. FY2021 OCF of A$13.4m was 139% of NPAT and 110% of underlying pre-AASB 16 EBITDA (derived), helped by JobKeeper and low working capital needs (patients pay at the point of service).

  • Maintenance capex is light at about 3% of statutory revenue.

  • Dividends absorbed roughly 70% of post-lease FCF, with the remainder funding bolt-on acquisitions and the preference-share investments.

  • There were no buybacks or capital raisings. Shares on issue were unchanged at 23,678,384, in line with the founder's long-stated priority of protecting EPS.

Ratios

Cash conversion cycle. This is not meaningful for this model. Inventory was negligible (A$0.4m), and patients settle at the time of service (Note 2). Receivable days are shown instead.

Commentary. Returns improved sharply in FY2021: ROE 22.5% and ROIC 16.3%, against a value-in-use WACC of 8.3% (Note 19). This indicates genuine value creation above the cost of capital, which underpins the 13.5x to 15.5x EV/EBITDA takeover multiples.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement

MetricFY2017FY2018FY2019FY2020FY2021

OTC revenue, non-IFRS (AUD Mn)

51.055.858.957.165.8

Statutory total revenue (AUD Mn)

36.239.342.040.69944.945

Consumables, lab fees and supplies (AUD Mn)

———5.1535.922

Gross profit, derived as revenue less consumables and lab (AUD Mn)

———35.54639.023

Employee benefits expense, net of JobKeeper (AUD Mn)

———14.20315.426

Reported EBITDA (AUD Mn)

——13.28416.17718.881

Underlying operating EBITDA (AUD Mn)

——10.51211.65215.244

Underlying operating EBITDA pre-AASB 16 (AUD Mn)

——10.5128.74612.184

Depreciation and amortisation (AUD Mn)

———5.5075.236

Operating income, derived as PBT plus finance costs (AUD Mn)

———10.67013.645

Finance costs (AUD Mn)

———0.8840.532

Profit before tax (AUD Mn)

———9.78613.113

Income tax expense (AUD Mn)

———2.6413.487

Net profit after tax (AUD Mn)

——7.87.1459.626

EPS basic, cents (FY2019 derived)

——32.830.240.7

EPS diluted, cents

———30.240.7

DPS ordinary declared for the year, cents

23.024.025.025.7514.5

Special DPS paid November 2021 (FY2022), cents

————100

Financial Analysis

ItemFY2019FY2020FY2021

Reported EBITDA

13,28416,17718,881

less JobKeeper receipts

0-1,805-2,185

less other one-off/non-operating revenue

-1,133-1,823-788

less other one-off/non-operating income

-1,639-897-664

Underlying operating EBITDA

10,51211,65215,244

less rent excluded under AASB 16

0-2,906-3,060

Underlying operating EBITDA pre-AASB 16

10,5128,74612,184

Margin Analysis (%)

MetricFY2017FY2018FY2019FY2020FY2021

Statutory revenue growth %

—8.66.9-3.110.4

OTC revenue growth %

-0.89.45.6-3.115.2

Gross margin, derived %

———87.386.8

Underlying EBITDA margin on statutory revenue %

——25.028.633.9

Underlying pre-AASB 16 EBITDA margin on OTC revenue %

——17.815.318.5

Operating (EBIT) margin, derived %

———26.230.4

Net margin on statutory revenue %

——18.617.621.4

Effective tax rate %

———27.026.6

Balance Sheet

MetricFY2019FY2020FY2021

Total assets (AUD Mn)

—74.15572.770

Cash and equivalents (AUD Mn)

0.6346.6814.247

Bank debt, short-term (AUD Mn)

—00

Bank debt, long-term (AUD Mn)

—15.00013.300

Lease liabilities, total (AUD Mn)

—8.8828.555

Net bank debt, derived (AUD Mn)

—8.3199.053

Net debt incl. leases, derived (AUD Mn)

—17.20117.608

Total equity (AUD Mn)

40.08541.13344.366

Goodwill (AUD Mn)

30.35731.63831.657

Total intangibles incl. goodwill (AUD Mn)

33.48234.30833.926

Working capital, current assets less current liabilities (AUD Mn)

—0.9170.633

Loans receivable, current plus non-current (AUD Mn)

—5.8228.310

Investment property (AUD Mn)

—1.6251.625

Cash Flow

MetricFY2017FY2018FY2019FY2020FY2021

Operating cash flow (AUD Mn)

———12.58413.375

Of which JobKeeper (AUD Mn)

———1.8052.185

Capex, PP&E plus intangibles (AUD Mn)

———1.7501.295

Free cash flow, OCF less capex (AUD Mn)

———10.83412.080

Lease principal repayments (AUD Mn)

———2.4803.060

FCF after lease payments, derived (AUD Mn)

———8.3549.020

Acquisitions net of cash, incl. deferred consideration (AUD Mn)

———1.9860.885

Dividends paid (AUD Mn)

———6.0976.393

Share buybacks (AUD Mn)

00000

Net borrowings drawn/(repaid) (AUD Mn)

———5.800-1.700

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2020FY2021

ROE on average equity, derived %

17.622.5

ROA on closing assets (FY2020) / average assets (FY2021), derived %

9.613.1

ROIC, NOPAT over (equity + debt + leases − cash), derived %

13.316.3

Current ratio, x

1.091.08

Bank debt to equity, x

0.360.30

Debt incl. leases to equity, x

0.580.49

Net bank debt to underlying pre-AASB 16 EBITDA, derived x

0.950.74

Company-reported net leverage ratio (covenant basis), x

—0.60

Interest coverage, EBIT over finance costs, derived x

12.125.6

Fixed-charge cover (covenant basis), x

—6.09

Asset turnover, derived x

0.550.61

Receivable days, derived

2013

Payout ratio, ordinary dividends paid over NPAT %

85.366.4

Region revenue

Region revenueFY2019FY2020FY2021

Australia, statutory revenue (AUD Mn)

42.040.69944.945

Australia, growth %

6.9-3.110.4

Rest of world (AUD Mn)

000

Geographic Revenue

IndicatorNorth QldCentral QldSouth East QldNSWSource

Goodwill, FY2021 (AUD Mn)

1.0246.55419.9814.098

Note 19

Goodwill change FY2020 to FY2021 (AUD Mn)

0.0150.3580-0.354

Note 19

Practice location pages, website 2026

77111

Website, October 2026

COVID-19 impact noted in 2H FY2021

Low

Low

Intermittent lockdowns

Intermittent lockdowns

Annual Report FY2021

Date / Period Details

Date / periodShare price (AUD)Source

May 2010

~2.89 (director transaction price)

InvestSMART

August 2015

7.09 (post-FY2015 result)

Business News Australia

September 2015

~7.00–7.08 (director buys)

InvestSMART

April 2016

~6.84–6.94

InvestSMART

June 2017

~6.49

InvestSMART

28 June 2019

6.35

Market Index

H2 CY2019 (Maven talks)

5.95

FNN

30 June 2020

5.16

Market Index (financials page)

August 2020 (FY2020 result)

6.30

FNN

30 June 2021

6.95

Market Index (financials page)

20 August 2021 (undisturbed)

7.02

Scheme announcement

12-month VWAP to 20 August 2021

6.79

Scheme announcement

Last trade (November 2021)

8.13

InvestSMART

Valuation Multiples

MultipleBlended (A$7.00; EV A$165m)Non-founder (A$8.00; EV A$188m)Basis

EV / underlying EBITDA pre-AASB 16 (x)

13.515.5

Company-stated, FY2021

P/E (x)

17.219.7

FY2021 EPS 40.7c, derived

EV / statutory revenue (x)

3.74.2

Derived

EV / OTC revenue (x)

2.52.9

Derived

P/B (x)

3.74.3

FY2021 equity A$44.4m, derived

DPS by fiscal year

DPS by fiscal yearFY2017FY2018FY2019FY2020FY2021

Interim DPS, cents

11.2512.012.513.2514.5

Final DPS, cents

11.7512.012.512.50

Total ordinary DPS, cents

23.024.025.025.7514.5

Analyst Conclusions

Guidance and consensus

There has been no management guidance since FY2021. The FY2021 outlook was qualitative: opportunistic acquisitions, organic growth and greenfield investigation. There is no sell-side consensus, as there was no broker coverage and the company is now private. Abano Healthcare publishes no 1300SMILES-specific targets.

Bull case

  1. Proven unit economics scale inside Abano. FY2021 ROIC of 16.3% against an 8.3% WACC. Group procurement and recruitment should lift brand-level margins above the standalone 33.9% underlying EBITDA margin.

  2. Regional Queensland is structurally under-served. Bolt-on acquisitions in Chinchilla and Bundaberg show a steady supply of vendor dentists seeking exits, which a well-capitalised owner can buy at accretive multiples.

  3. Demand tailwinds. Ageing demographics, cosmetic and orthodontic growth, and FY2021 OTC growth of 15% with same-store sales 8% above pre-COVID indicate durable demand.

Bear case

  1. Footprint contraction. About 26 listed locations in 2026 versus 33 at acquisition may signal closures or transfers into Maven, eroding the brand's standalone value.

  2. Labour constraints. Dentist supply and retention risk is amplified in regional markets. Abano's 2026 international recruiting suggests persistent shortages.

  3. Policy and payer risk. The CDDS precedent (−29.5% half-year revenue) and insurer network pricing can compress fees. Discounted new-patient offers (A$249) point to a price-competitive acquisition environment.

Catalysts and monitorables (next 12 months)

  • Any Abano/BGH/OTPP exit process (sale or IPO of the trans-Tasman platform) that would re-surface 1300SMILES financials.

  • Disclosure of whether the founders' retained ~16% stake was acquired by the Abano parent.

  • Changes to the CDBS or any new federal or state dental funding scheme.

  • Practice count trajectory on the 1300SMILES website (26 as of October 2026).

  • Health-fund network renegotiations.

  • Abano group leverage and refinancing activity.

Analyst verdict

1300SMILES Limited is a closed chapter as a public equity but a live operating brand. Judged on its listed record, it was one of the better-run small-cap healthcare services businesses on the ASX:

  • Statutory revenue grew from A$22.4m in FY2009 to A$44.9m in FY2021.

  • Net margins expanded above 20%.

  • The share count was held flat in the final years.

  • It paid an unbroken stream of fully franked dividends from 2005.

  • It balanced conservative leverage against selective acquisitions.

Its FY2021 result was its best, with A$65.8m OTC revenue, A$12.2m underlying pre-AASB 16 EBITDA and A$9.6m NPAT. That result was effectively the vendor's "high-water mark" sale document. The BGH/OTPP-backed Abano paid 13.5x blended (15.5x for minorities) EBITDA, a full but defensible price for a business earning a mid-teens ROIC with a long reinvestment runway in regional Queensland.

The structure was founder-friendly in an unusual way. Minorities received a 14% to 18% premium in cash. The founder accepted lower cash per share, partly contingent, and rolled about 16% of the company into the private platform. This alignment signalled confidence in the platform thesis.

The weaknesses were governance-related and are now largely moot: a small board, related-party leases, a dominant founder and an idiosyncratic treasury investment in preference shares. The open questions concern stewardship under private-equity ownership. The branded footprint appears to have shrunk to about 26 listed locations. No financial disclosure has been made since 2021, and whether the founder's retained stake was rolled into parent scrip is unknown.

Verdict. For anyone assessing exposure today, whether as a counterparty, potential acquirer of the Abano platform, landlord, or dentist, 1300SMILES should be treated as a high-quality regional asset embedded in a leveraged private platform. Its intrinsic economics are strong; its transparency is nil. Any valuation work requires primary diligence data.


Primary sources referenced

  • 1300SMILES Limited Annual Report and Appendix 4E, FY2021 (ASX, 24 August 2021)

  • ASX announcement "Abano Healthcare to acquire 1300Smiles", including the Scheme Implementation Agreement dated 23 August 2021 (ASX, 24 August 2021)

  • ASX announcement "Implementation of Scheme" (1 December 2021); "Removal from Official List" (2 December 2021)

  • 1300SMILES Annual Report FY2016 (ASX, 11 August 2016)

  • Company press releases and blogs (dentalcommunity.com.au; 1300smiles.com.au)

  • 1300SMILES website (accessed October 2026)

  • Business News Australia; Finance News Network; Stockhead; Kalkine; AFR; NBR; Dental Tribune; DealStreetAsia

  • Aggregators used only for corroboration: InvestSMART, Market Index, MarketBeat

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenurePrior roles and educationFY2021 total remuneration (AUD)

Robert Jones

Independent Non-Executive Chairman; IBC Chair for the Scheme

Chair from 25 September 2007 (director and chair since 2007) to 1 December 2021

Director and Chair, Mater Health Services North Qld (1993–2013); director, Hermit Park Bus Service; MAICD

42,160 (fees 36,864 + super 5,296)

Dr Daryl Holmes OBE

Founder and Managing Director

Director 18 September 2000 to 1 December 2021; MD agreement from 8 March 2005

B.D.Sc (Hons), UQ (1987); RAAF Dental Officer (1988–91); private practice from 1991; Chairman, Cowboys Leagues Club (from May 2014; director for 19 years); ADA member for 34 years; MAICD

91,326 (salary 83,403 + super 7,923). Also earns income as a practising dentist under a DSA on commercial terms

Jason Smith

Independent Non-Executive Director; IBC member

23 November 2017 to 1 December 2021

Founder and Executive Chairman, Back In Motion Health Group (100+ locations AU/NZ); author; Franchise Council of Australia member

30,000

Evonne Collier

Non-Executive Director

Resigned 6 April 2020

—

22,500 (FY2020)

Natalie Duve

Operations Manager (KMP)

From 18 October 2017

—

172,502 (salary 157,536 + super 14,966). Contract: A$168,630 package plus up to 10% STI

Roman Chideme

Financial Controller (KMP)

From 30 September 2019

—

150,753. Contract: A$140,525 plus A$15,000 STI

Patrick Wyatt

Company Secretary

Throughout FY2021

——

“—” = not publicly disclosed.

Major Shareholders

HolderSharesStake %DateSource

Dr Daryl Holmes and associated entities (TFD Hybrid Fixed Trust; Golden Arch (Qld) Pty Ltd ATF Whistler Discretionary Trust)

14,711,72962.13

Pre-scheme

Annual Report FY2021; InvestSMART

Ellerston Capital Limited and associates

1,680,6287.1

August 2021

Scheme announcement, 24 August 2021

Robert Jones

37,5210.16

June 2021

Annual Report FY2021

Natalie Duve

26,6920.11

June 2021

Annual Report FY2021

Jason Smith

2,0680.01

June 2021

Annual Report FY2021

Shares held under escrow (share-loan plan)

333,3241.41

June 2021

Note 25

Competitive Landscape

Key Competitors

CompetitorTypeScale indicatorRelative positioning vs 1300SMILESSource

Pacific Smiles Group (ex-ASX: PSQ)

Corporate DSO; independent-dentist centre model

FY2019 revenue A$122.2m; NPAT A$8.9m; 89 centres; FY2019 patient fees A$187.4m. Taken private in 2024 (verify)

Same service-fee model at roughly 3x scale; greenfield-led in NSW, Victoria and Queensland; lower margins

Kalkine, December 2019

Maven Dental Group (Abano)

Corporate DSO

106–116 Australian practices (2019–2021)

Now a sister brand; was the largest acquisition target and a competitor for practices pre-2021

ASX announcement, 24 August 2021; Business News Australia

National Dental Care

Private DSO

60+ surgeries (circa 2018); attempted IPOs 2018 and ~2021

Direct competitor for acquisitions and dentists

AFR; Stockhead

Smiles Inclusive (ex-ASX: SIL)

Corporate DSO

FY2019 statutory loss A$31.0m; practice revenue net of direct costs A$30.4m; debt/equity ~7x

Distressed peer; sold practices to 1300SMILES in December 2019.

Kalkine, November 2019

Bupa Dental

Insurer-owned clinics

—

Vertically integrated pricing advantage for Bupa members

General knowledge

HCF Dental Centres

Insurer-owned clinics

—

Member no-gap offers; strong in NSW

General knowledge

Medibank Members' Choice network

Insurer preferred-provider network

—

1300SMILES is a preferred provider; network terms constrain pricing

Website

Queensland Health Oral Health Services

Public dental

Not applicable

Free or subsidised care for eligible adults and children; competes for low-income patients

General knowledge

Independent owner-operated practices

Fragmented

The majority of the market

Main competitors locally; also the acquisition pipeline

Annual Report FY2021 (acquisition strategy)

SDI Limited (ASX: SDI)

Dental materials manufacturer

FY2019 sales A$79.6m

Supplier, not competitor; included for sector benchmarking

SDI FY2019 results

“—” = not publicly disclosed.

Peer Comparison FY2021

Metric1300SMILES (FY2021)Pacific Smiles (FY2019)Smiles Inclusive (FY2019)Maven Dental (2021)

Revenue (AUD Mn)

44.9 statutory / 65.8 OTC

122.2

30.4 practice revenue net of direct costs

—

Revenue growth %

10.416.9——

NPAT (AUD Mn)

9.68.9-31.0—

Net margin %

21.4

7.3 (derived)

Negative

—

Practices

3389—106

R&D intensity %

0000

“—” = not publicly disclosed.

Recent Developments

Data limitation: * As a private subsidiary since December 2021, 1300SMILES publishes no market announcements. Part A records everything verifiable in the window.

Part A — 18-month window

DateEventSignificanceSource
2025–2026No material corporate announcements (results, guidance, litigation, regulatory actions) identified for 1300SMILES LtdConsistent with private statusWeb search, October 2026
2026 (ongoing)Website lists 26 locations across 4 regions, copyright "2026 1300SMILES Ltd"Brand retained as a distinct trading name within Abano; footprint below the 33 practices of August 2021Website
2026 (to 15 January 2027)New-patient check-up, clean and x-ray offer at A$249 at participating practicesPrice-led patient acquisition; signals a competitive new-patient marketWebsite
31 July 2026Dental Health Week 2026 campaign content publishedContinuing brand marketingWebsite blog
2,026Abano Healthcare recruits clinicians internationally (e.g., British Dental Conference 2026); former 1300SMILES personnel involvedDentist-supply constraints persist; group-level recruitment modelPublic professional-network posts (low confidence)
2,026Recruitment for 1300SMILES routed via careers.abanohealthcare.comShared-services integrationWebsite

Part B — Extended register (final listed period)

DateEventSignificanceSource
2 December 2021Removed from the ASX Official ListEnd of public disclosureASX
1 December 2021Scheme implemented; final director's interest notices filedChange of controlASX
26 November 2021A$1.00 fully franked special dividend paidDistributes franking credits (A$10.8m balance at June 2021)ASX
18 November 2021Suspension from quotationScheme effectiveASX
17 November 2021Court approval; Scheme effectiveFinal legal stepASX
12 November 2021Scheme meetings and AGM pass; dividend notice; JobKeeper payments notificationShareholder approvalASX
13 October 2021Scheme Booklet registered with ASICDisclosure to voteASX
31 August 2021Appendix 4G and Corporate Governance StatementComplianceASX
24 August 2021Consortium holding notice; MD letter; SIA announcement; FY2021 resultsDeal announced; shares +15.8% to ~A$8.13ASX; InvestSMART
23 August 2021Trading halt and pause in tradingPre-dealASX
August 2021Fourth Bundaberg practice contractedGrowth continuationAnnual Report FY2021
1 July 2021Chinchilla acquisition settledWestern Downs entryAnnual Report FY2021
2H FY2021SEQ/NSW lockdowns affect select practicesRevenue moderationAnnual Report FY2021
1 April 2021Confidentiality agreement with AbanoDeal originationSIA
18 March 202114.5c interim dividend paidRecord interimInvestSMART
7 December 2020Bundaberg Central Point acquiredCentral Queensland densityAnnual Report FY2021
11 September 202012.5c final FY2020 dividend paidDividend continuity through COVIDAnnual Report FY2021
August 2020FY2020 results; record June revenueResilienceFNN
21 April 2020Director J. Smith buys 1,997 shares at ~A$5.06Insider confidence at COVID troughInvestSMART
April 2020~50% of practices open part-time; cash conservationCOVID shockKalkine
6 April 2020Director E. Collier resignsBoard shrinks to threeAnnual Report FY2021
February 20201H FY2020 EBITDA +31.6%; MD letter on Maven and SILStrategy disclosureBusiness News Australia

Company Snapshot

338

Employees

1991

Founded

Townsville, Australia

Headquarters

SWOT Analysis

Strengths

  • High, improving profitability. FY2021 net margin was 21.4% and underlying EBITDA margin on statutory revenue was 33.9% (Annual Report FY2021, derived).
  • Conservative balance sheet. Net leverage was 0.60x against a 2.75x covenant, and fixed-charge cover was 6.09x (Note 24).
  • Strong cash conversion. FY2021 OCF of A$13.4m was 139% of NPAT; capex was only A$1.3m.
  • Capital discipline. Shares on issue were unchanged at 23,678,384 across FY2020–FY2021, and the dividend record was unbroken from listing (22 consecutive fully franked dividends by 2015, continuing to 2021).
  • Resilience. Same-store sales were 8% above FY2019 by FY2021 despite COVID-19 (MD letter, FY2021).
  • Exit validation. The takeover at 13.5x to 15.5x EV/EBITDA by sophisticated private-equity owners (announcement, 24 August 2021).

Weaknesses

  • Geographic concentration. All goodwill sits in Queensland and NSW, with 63% in SEQ (Note 19).
  • Thin governance. A three-director board, no women directors, and no audit committee (Annual Report FY2021).
  • Related-party dependence. A$0.69m of rent was paid to founder entities in FY2021.
  • Goodwill-heavy balance sheet. NTA was 44.0c per share and goodwill was 71% of equity (Appendix 4E).
  • Non-core financial assets. A$6.0m of preference shares in an unlisted company (Note 14).
  • Small scale. 33 practices versus 89 (Pacific Smiles) and 106 (Maven) limited procurement and marketing leverage.

Opportunities

  • Platform synergies within Abano. Procurement, IT, recruitment and marketing are shared across a 100+ practice Australian network (announcement, 24 August 2021; website careers link).
  • Regional Queensland roll-up. Chinchilla and a fourth Bundaberg practice show a pipeline of vendor-dentist exits (Annual Report FY2021).
  • Higher-value services. Orthodontics, implants and cosmetics are already offered (website).
  • Membership and financing models. These can lift visit frequency; Abano reports success with subscription models at Lumino (RNZ coverage).
  • Third-party facility management, a stated but under-developed growth driver.
  • Dentist productivity programs. OTC grew 15% in FY2021 against modest site growth.

Threats

  • Policy shocks. The CDDS closure precedent: 1H FY2014 revenue −29.5% (press release, February 2014).
  • Pandemic or lockdown recurrence. FY2020 underlying pre-AASB 16 EBITDA fell 17%.
  • Dentist attrition. The SIA treated loss of DSAs representing 15% of production as a prescribed event, showing concentration sensitivity.
  • Insurer network pricing pressure. Eight preferred-provider funds are listed on the website.
  • Integration risk. Brand footprint fell from 33 practices (2021) to about 26 listed locations (2026).
  • Private-equity leverage at the group level, which may constrain capex and pricing (financing via debt commitment letters, SIA).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2025–2026No material corporate announcements (results, guidance, litigation, regulatory actions) identified for 1300SMILES Ltd Web search, October 2026Consistent with private status
2026 (ongoing)Website lists 26 locations across 4 regions, copyright "2026 1300SMILES Ltd"Brand retained as a distinct trading name within Abano; footprint below the 33 practices of August 2021
2026 (to 15 January 2027)New-patient check-up, clean and x-ray offer at A$249 at participating practices WebsitePrice-led patient acquisition; signals a competitive new-patient market
31 July 2026Dental Health Week 2026 campaign content published Website blogContinuing brand marketing
2026Abano Healthcare recruits clinicians internationally (e.g., British Dental Conference 2026); former 1300SMILES personnel involved Public professional-network posts (low confidence)Dentist-supply constraints persist; group-level recruitment model
2026Recruitment for 1300SMILES routed via careers.abanohealthcare.com WebsiteShared-services integration
2 December 2021Removed from the ASX Official ListEnd of public disclosure
1 December 2021Scheme implemented; final director's interest notices filed ASXChange of control
26 November 2021A$1.00 fully franked special dividend paid ASXDistributes franking credits (A$10.8m balance at June 2021)
18 November 2021Suspension from quotation ASXScheme effective
17 November 2021Court approval; Scheme effective ASXFinal legal step
12 November 2021Scheme meetings and AGM pass; dividend notice; JobKeeper payments notification ASXShareholder approval
13 October 2021Scheme Booklet registered with ASIC ASXDisclosure to vote
31 August 2021Appendix 4G and Corporate Governance Statement ASXCompliance
24 August 2021Consortium holding notice; MD letter; SIA announcement; FY2021 results ASX; InvestSMARTDeal announced; shares +15.8% to ~A$8.13
23 August 2021Trading halt and pause in trading ASXPre-deal
August 2021Fourth Bundaberg practice contracted Annual Report FY2021Growth continuation
1 July 2021Chinchilla acquisition settled Annual Report FY2021Western Downs entry
2H FY2021SEQ/NSW lockdowns affect select practices Annual Report FY2021Revenue moderation
1 April 2021Confidentiality agreement with Abano SIADeal origination
18 March 202114.5c interim dividend paid InvestSMARTRecord interim
7 December 2020Bundaberg Central Point acquired Annual Report FY2021Central Queensland density
11 September 202012.5c final FY2020 dividend paid Annual Report FY2021Dividend continuity through COVID
August 2020FY2020 results; record June revenue FNNResilience
21 April 2020Director J. Smith buys 1,997 shares at ~A$5.06 InvestSMARTInsider confidence at COVID trough
April 2020~50% of practices open part-time; cash conservation KalkineCOVID shock
6 April 2020Director E. Collier resigns Annual Report FY2021Board shrinks to three
February 20201H FY2020 EBITDA +31.6%; MD letter on Maven and SIL Business News AustraliaStrategy disclosure

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Income Statement: Revenue & Gross Profit: OTC revenue, non-IFRS rose from AUD 51 Mn in FY2017 to AUD 65.8 Mn in FY2021.
1300SMILES Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2017FY2018FY2019FY2020FY2021
OTC revenue, non-IFRS5155.858.957.165.8
Statutory total revenue36.239.34240.744.9
Gross profit as revenue less consumables and lab———35.539

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.